While there appears to be intratumor heterogeneity in hormone receptor expression, both between well- and de-differentiated areas of the same tumor, and over time within a patient’s tumor (which may be partially attributable to biopsy bias), endocrine therapeutics may be useful to control hormone receptor-driven LS cells and mitigate disease progression. This evidence concerns the gene NR4A1 and neoplasm.